Purpose

Prospective, non-randomized, multicenter clinical investigation to assess the safety and effectiveness of AMDS in the treatment of patients with acute DeBakey type I dissection, with evidence of malperfusion, through open surgical repair.

Condition

Eligibility

Eligible Ages
Between 18 Years and 80 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • ≥18 years of age or ≤80 years of age (male or female) at time of surgery - Acute DeBakey type I dissection based on computed tomography angiography (CTA) and diagnosed ≤14 days from of the index event - Presence of malperfusion (cerebral, visceral, renal, spinal cord, and/or peripheral)

Exclusion Criteria

  • Other medical condition that is associated with limited life expectancy <2 years (e.g., cancer, congestive heart failure) - Pregnant or breastfeeding. - Unwilling to comply with the follow-up schedule - Institutionalized due to administrative or judicial order - Unwilling to accept blood transfusions for any reason - Coronary malperfusion - In circulatory shock (i.e., systolic blood pressure <90 mmHg) at time of screening - In extreme hemodynamic compromise requiring cardiopulmonary resuscitation at time of screening - Suspicion of bowel necrosis (as determined by the implanting physician based on imaging observations, peritoneal signs, surgical exploration, elevated serum lactate levels, low pH, and/or acidosis) - Clinical or radiographic signs of bowel infarction or gastrointestinal hemorrhage - Base deficit > -10 mmol/L or -10 mEq/L - American Society of Anesthesiologists risk class V (i.e., moribund patient not expected to live 24 hours with or without operation) or class VI (a declared brain dead patient whose organs are being removed for donor purposes) - Previous placement of a thoracic endovascular graft - Interventional and/or open surgical procedures 30 days prior to the dissection repair - Planned major interventional and/or open surgical procedures 30 days post the dissection repair - Systemic infection - Uncontrollable anaphylaxis to iodinated contrast (patients with allergy to iodinated contrast but not anaphylaxis may be eligible with appropriate pre-medication, as deemed suitable by the Investigator) - Known allergy(ies) to nitinol and/or polytetrafluoroethylene - Inability to obtain CT angiograms for follow-up - Previously diagnosed with Marfan syndrome, Ehlers-Danlos syndrome, or Loeys-Dietz syndrome based on laboratory genetic testing - Diagnosed with acute myocardial infarction in the 30 days prior to the dissection diagnosis - Diagnosed with severe and catastrophic neurological complications in the 30 days prior to the dissection diagnosis (namely, obtundation or coma) - Current Stage 5 end stage chronic kidney disease (eGFR ≤ 15 mL/min) - History of bleeding disorder (i.e. hemophilia) - A primary entry tear that extends into the arch or distal to the left subclavian artery - Need for a total aortic arch replacement and/or repair, or reconstruction, of any part of the arch, and branch vessels (including extra-anatomic bypass of the branch vessels), for any reason as deemed necessary by the Investigator - Any pathology of mycotic origin - Aortic fistulous communication with non-vascular structure (e.g., esophagus, bronchial) - Extensive thrombus or calcifications in the aortic arch, as defined by CTA - Excessive tortuosity precluding safe passage of the AMDS, as defined by CTA - Descending thoracic aneurysm involving the proximal third (one-third) of the descending aorta and measuring >45 mm in diameter - Aortic arch aneurysm >50 mm in diameter

Study Design

Phase
N/A
Study Type
Interventional
Allocation
N/A
Intervention Model
Single Group Assignment
Intervention Model Description
Primary Cohort (n=93) and Continued Access (n=40)
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Acute DeBakey Type I Dissection
In eligible patients, the ascending aorta is transected and removed in a routine standard of care manner utilizing hypothermic circulatory arrest; the operator will leave at least 10 mm (1.0 cm) aortic tissue proximal to the innominate artery. AMDS is pre-loaded onto the delivery system and is delivered into the true lumen through the open distal aorta and implanted according to the instructions for use.
  • Device: AMDS
    AMDS Implantation

Recruiting Locations

University of Alabama at Birmingham
Birmingham, Alabama 35294
Contact:
Dorothy Neithers

More Details

Status
Recruiting
Sponsor
Artivion Inc.

Study Contact

Erin Adams, BSc, MSPH
(770) 419-3355
erin.adams@artivion.com

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.